人前列腺癌异种移植模型的mRNA/miR与蛋白互作网络揭示全身播散机制
本研究基于人前列腺癌异种移植瘤模型(PC-3高、VCaP中、DU-145弱自发微转移潜能),比较mRNA、miR和蛋白表达,构建播散相关互作网络,发现EMT通路及CD46、DDX21两个汇聚节点,并在临床和功能实验中验证其预后价值与促转移作用。
要点
- 基于异种移植瘤自发微转移潜能差异构建播散相关mRNA/miR与蛋白互作网络。
- CD46随转移潜能降低、DDX21随转移潜能升高,两者均提供预后信息。
- CD46缺失可独立预测不良结局,并在体外诱导EMT样属性、体内促进自发微转移。
核心结论
- 播散相关互作网络中的多个新候选分子具有直接促转移和临床相关作用,值得进一步研究。
研究设计与样本
- 比较PC-3(高)、VCaP(中)、DU-145(弱)自发微转移潜能的人前列腺癌异种移植瘤的mRNA、miR和蛋白表达水平。
- 聚焦组间差异调控且已知相互作用的mRNA、miR和蛋白,构建播散相关mRNA/miR与蛋白/miR网络。
- 通过独立人前列腺癌模型ARCAP-E/-M及临床和功能实验进行验证。
主要发现
- 互作网络包含已知的前列腺癌进展和/或转移决定因子以及多个新候选分子。
- EMT通路在前列腺癌播散中起明确作用,并被独立模型ARCAP-E/-M证实。
- CD46随转移潜能降低,DDX21随转移潜能升高,两者均一致提供预后信息。
- CD46缺失可独立于已确立参数预测不良结局。
- 在弱转移性前列腺癌细胞中敲低CD46可在体外诱导EMT样属性并在体内促进自发微转移形成。
临床怎么用
- CD46缺失和DDX21升高可作为前列腺癌预后评估的候选分子标志物。
- CD46缺失可独立于已确立参数预测不良结局,提示其用于风险分层的潜力。
- 靶向CD46相关EMT通路可能为抑制前列腺癌播散提供方向。
局限性
- 研究基于异种移植模型和概念验证实验,结论需进一步临床转化验证。
- 原文未报告具体样本量、随访细节及多变量模型参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Distant metastasis formation is the major clinical problem in prostate cancer (PCa) and the underlying mechanisms remain poorly understood. Our aim was to identify novel molecules that functionally contribute to human PCa systemic dissemination based on unbiased approaches. METHODS: We compared mRNA, microRNA (miR) and protein expression levels in established human PCa xenograft tumours with high (PC-3), moderate (VCaP) or weak (DU-145) spontaneous micrometastatic potential. By focussing on those mRNAs, miRs and proteins that were differentially regulated among the xenograft groups and known to interact with each other we constructed dissemination-related mRNA/miR and protein/miR networks. Next, we clinically and functionally validated our findings. RESULTS: Besides known determinants of PCa progression and/or metastasis, our interaction networks include several novel candidates. We observed a clear role of epithelial-to-mesenchymal transition (EMT) pathways for PCa dissemination, which was additionally confirmed by an independent human PCa model (ARCAP-E/-M). Two converging nodes, CD46 (decreasing with metastatic potential) and DDX21 (increasing with metastatic potential), were used to test the clinical relevance of the networks. Intriguingly, both network nodes consistently added prognostic information for patients with PCa whereas CD46 loss predicted poor outcome independent of established parameters. Accordingly, depletion of CD46 in weakly metastatic PCa cells induced EMT-like properties in vitro and spontaneous micrometastasis formation in vivo. CONCLUSIONS: The clinical and functional relevance of the dissemination-related interaction networks shown here could be successfully validated by proof-of-principle experiments. Therefore, we suggest a direct pro-metastatic, clinically relevant role for the multiple novel candidates included in this study; these should be further exploited by future studies.
引用
- Lange T, Samatov TR, Galatenko VV, et al. Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. Eur J Cancer. 2020. PMID: 32750503. doi:10.1016/j.ejca.2020.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。